MX2020007494A - Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. - Google Patents

Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas.

Info

Publication number
MX2020007494A
MX2020007494A MX2020007494A MX2020007494A MX2020007494A MX 2020007494 A MX2020007494 A MX 2020007494A MX 2020007494 A MX2020007494 A MX 2020007494A MX 2020007494 A MX2020007494 A MX 2020007494A MX 2020007494 A MX2020007494 A MX 2020007494A
Authority
MX
Mexico
Prior art keywords
metronidazole
methods
treating
infection
same
Prior art date
Application number
MX2020007494A
Other languages
English (en)
Inventor
Jr Bernard J Guarino
Jamie L Doran
Zorana Radovic
Kevin Sullivan
Original Assignee
Appili Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Appili Therapeutics Inc filed Critical Appili Therapeutics Inc
Publication of MX2020007494A publication Critical patent/MX2020007494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas orales que comprenden: 1) metronidazol o una sal farmacéuticamente aceptable del mismo; y silicato de aluminio y magnesio; o 2) metronidazol o una sal farmacéuticamente aceptable del mismo; silicato de aluminio y magnesio; y un agente saborizante. También se proporcionan métodos de tratamiento de la infección utilizando las composiciones farmacéuticas orales.
MX2020007494A 2018-01-16 2019-01-16 Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. MX2020007494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862617703P 2018-01-16 2018-01-16
PCT/CA2019/050053 WO2019140516A1 (en) 2018-01-16 2019-01-16 Oral formulations of metronidazole and methods of treating an infection using same

Publications (1)

Publication Number Publication Date
MX2020007494A true MX2020007494A (es) 2020-10-12

Family

ID=67301642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007494A MX2020007494A (es) 2018-01-16 2019-01-16 Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas.

Country Status (6)

Country Link
US (2) US11541035B2 (es)
EP (1) EP3768321A4 (es)
BR (1) BR112020014376A2 (es)
CA (1) CA3087789A1 (es)
MX (1) MX2020007494A (es)
WO (1) WO2019140516A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768321A4 (en) * 2018-01-16 2022-05-04 Appili Therapeutics Inc. ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING INFECTION USING THE SAME

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013058496A1 (en) * 2011-10-21 2013-04-25 Daewoong Pharmaceutical Co., Ltd. Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
CN103393596A (zh) * 2013-07-01 2013-11-20 北京安汀医药生物科技有限公司 一种甲硝唑的混悬液及其制备方法
EP3768321A4 (en) * 2018-01-16 2022-05-04 Appili Therapeutics Inc. ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING INFECTION USING THE SAME

Also Published As

Publication number Publication date
US20210069153A1 (en) 2021-03-11
EP3768321A1 (en) 2021-01-27
EP3768321A4 (en) 2022-05-04
US11541035B2 (en) 2023-01-03
US20230086660A1 (en) 2023-03-23
CA3087789A1 (en) 2019-07-25
WO2019140516A1 (en) 2019-07-25
BR112020014376A2 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
AR119159A1 (es) Tratamientos de angioedema
GEP20247585B (en) Furoindazole derivatives
JOP20210230A1 (ar) صياغات صيدلانية
MX2020007494A (es) Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas.
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
PH12020551772A1 (en) Oxo-substituted compound
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
MX2021005390A (es) Ingredientes farmaceuticos activos amorfos novedosos que comprenden carbonato de magnesio mesoporoso sustancialmente amorfo.
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
PH12021550323A1 (en) Dendrimer formulations
PH12020500120A1 (en) Pharmaceutical compositions